BEIJING—Jiyuan Biotechnology, a leading Chinese biopharmaceutical company, has secured tacit clinical trial approval from the National Medical Products Administration (NMPA) for its cutting-edge therapy targeting type 2 diabetes. This marks the first clinical trial approval in China for domestically developed gene-modified mesenchymal stem cells.
The therapy in question involves the use of human GLP-1 and FGF21-highly expressed adipose-derived stem cells (ADSCs), an innovative approach that leverages the patients’ own abdominal fat. Jiyuan Bio’s proprietary stem cell and gene modification technology platforms are utilized to incorporate the therapeutic agents GLP-1 and FGF21 into the stem cells, offering a novel treatment for patients with refractory type 2 diabetes.
The injectable treatment, a cryopreservation type stem cell preparation, represents a significant advancement in the field of regenerative medicine. Jiyuan Biotechnology’s development of this therapy aligns with the growing global interest in stem cell-based solutions for metabolic diseases and other challenging health conditions.
As the company moves forward with clinical trials, the potential impact of this therapy on the treatment landscape for type 2 diabetes in China and beyond will be closely watched by the medical community and investors alike.- Flcube.com
